Condition: Metastatic Solid Tumor · Ovarian Cancer · Breast Cancer · Sponsor: Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 with Olaparib in adult patients with locally advanced or metastatic solid tumors
This description comes directly from the study's public registry record.
Duo Wu · +86-571-86360796 · wuduo@synrx.cn
Always discuss trial participation with your own doctor first.
| FuDan University Shanghai Cancer Center | Shanghai, Shanghai Municipality, China | Recruiting |
| FuDan University Shanghai Cancer Center | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07156253